XML 36 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings (Loss) Per Share
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Earnings (Loss) Per Share Earnings (Loss) Per Share
Basic income (loss) per share applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted-average number of common shares outstanding. Diluted income (loss) per share assumes the conversion of any convertible securities using the treasury stock method or the if-converted method.
 
 Three Months Ended June 30,Six Months Ended June 30,
(In thousands, except per share data)2022202120222021
Numerator:
Net loss attributable to UpHealth, Inc.$(12,438)$(32,783)$(29,883)$(35,732)
Denominator:
Weighted average shares outstanding(1)
144,624 94,170 144,581 83,585 
Weighted average shares outstanding assuming dilution144,624 94,170 144,581 83,585 
Net loss per share attributable to UpHealth, Inc.:
Basic$(0.09)$(0.35)$(0.21)$(0.43)
Diluted$(0.09)$(0.35)$(0.21)$(0.43)
(1) The shares and earnings per share available to our common stock holders, prior to the Business Combinations, have been recast to reflect the exchange ratio established in the Business Combinations (1.0 UpHealth Holdings share to 10.28 GigCapital2 share). See Note 3, Business Combinations, for more information.
For the three months ended June 30, 2022, the calculation of dilutive earnings per share excluded outstanding warrants to purchase 18.1 million shares of common stock at $11.50 per share; 0.2 million of stock options; and senior convertible notes, convertible into 15.0 million shares of common stock at $10.65 per share, because the effect would be anti-dilutive. For the six months ended June 30, 2022, the calculation of dilutive earnings per share excluded outstanding warrants to purchase 18.1 million shares of common stock at $11.50 per share; 0.2 million of stock options; senior convertible notes and convertible into 15.0 million shares of common stock at $10.65 per share; and 1.7 million shares of treasury stock acquired under the terms of the forward share purchase agreement, because the effect would be anti-dilutive.